# BPC-157 Legal Status, FDA 503A Category, and Compounding Access | Safe BPC-157 > BPC-157 legal status: not an FDA-approved drug; FDA placed it in 503A Category 2 effective September 29, 2023, and it is individually named on the July 23-24, 2026 PCAC agenda as a substance under evaluation. Where BPC-157 actually stands under U.S. compounding law — the current FDA category, the scheduled 2026 advisory-committee review, and how lawful compounded access works. General information, not legal or medical advice. ## Access is under active FDA review — and the current status is fixed The most current development in BPC-157 legal status is forward-looking: access is under active FDA review and may change in 2026. BPC-157 is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, listed — alongside KPV, TB-500, and MOTs-C — as a bulk drug substance "being considered for inclusion on the 503A Bulks List" [21][24]. That is real momentum: the agency has put this specific peptide on a formal evaluation calendar. It is also, precisely, a scheduled discussion. A PCAC meeting is advisory; being considered for the bulks list is a step in evaluation, not a listing decision, not a reclassification, and not a change in the current status [20][21]. What follows is the status as it stands today, stated in the present tense and sourced to the FDA. ## The current fact: 503A Category 2 BPC-157 — which the FDA evaluated under the list entries "BPC-157 (free base)" and "BPC-157 acetate" — is a research peptide that the FDA placed in 503A Category 2: bulk drug substances that may present significant safety risks [22]. The placement took effect with the FDA's September 29, 2023 update to the list of substances nominated for use under section 503A, citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization [22]. The practical meaning of Category 2 is specific. As a Category 2 substance, BPC-157 is not within the FDA's enforcement-discretion policy for 503A compounding — the policy that, for Category 1 substances, lets compounding proceed during evaluation does not apply here [20][22]. And separately, BPC-157 is not an FDA-approved drug; whether a finished drug is approved (via a New Drug Application) is a different question from whether a bulk substance may be used in compounding, and BPC-157 satisfies neither [20]. ## What the July 2026 advisory-committee meeting is — and is not It is worth being exact about the 2026 review, because this is where misreading happens. The FDA's public calendar lists BPC-157 (as "BPC-157 (free base)" / "BPC-157 acetate") among the substances to be discussed at the July 23-24, 2026 PCAC meeting as candidates "being considered for inclusion on the 503A Bulks List" [21]. Inclusion on a final bulks list is decided by FDA rulemaking informed by the committee; being discussed by the PCAC is part of evaluation, not the outcome of it [20]. No outcome should be assumed. The meeting may be referenced as a scheduled discussion of a substance under evaluation — nothing more. This page does not state, date, or imply any reclassification, listing, or removal as a settled fact, because none has been confirmed from an authoritative FDA source [20]. Reports circulating in early 2026 of a broad reclassification, or of BPC-157 being "removed" from Category 2 on a specific date, could not be verified against the FDA and are not treated here as having occurred — and the live PCAC agenda, which still lists BPC-157 as under consideration, is consistent with the evaluation being ongoing rather than resolved. ## How lawful compounded peptide access works Independent of any one substance, U.S. compounding law has a defined shape worth understanding in general terms. A legally compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription [25]. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger office or batch volumes, sourced from an FDA-registered 503B outsourcing facility [25]. Telehealth fits at the front of this pathway, not around it. A compliant telehealth encounter can be the channel through which a patient is evaluated and a prescription issued, but it does not change which substances are eligible to be compounded and it does not remove the need for a legitimate prescriber-patient relationship and a valid prescription [25]. There is one decisive caveat for BPC-157: a compounder may use a bulk active ingredient only if it is permitted under the 503A/503B framework, and an ingredient the FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands [25]. As a Category 2 substance, BPC-157 sits under exactly that constraint today [22]. This site names no pharmacy, clinic, telehealth provider, or vendor, gives no dosing, and describes no way to obtain any substance outside the lawful framework. ## Beyond the FDA: WADA One more line of the record matters for athletes. BPC-157 is prohibited in sport at all times by the World Anti-Doping Agency under its S0 non-approved-substances category, which covers substances not approved by any government health authority for human therapeutic use. For anyone subject to anti-doping rules, that prohibition is independent of the compounding question and applies regardless of how a substance is obtained. Taken together, the regulatory picture is consistent: not FDA-approved, placed in 503A Category 2 in 2023 and not within enforcement discretion, individually scheduled for advisory-committee discussion in July 2026 with no decided outcome, and prohibited in sport. That is the present-tense record, and it is what any read of access should start from. ## Is BPC-157 legal? BPC-157 is not an FDA-approved drug and is sold by research suppliers for laboratory use only [22]. The FDA placed it in 503A Category 2 — bulk substances that may present significant safety risks — effective September 29, 2023, so it is not within the enforcement-discretion policy for 503A compounding while that status stands [20][22]. ## Can you get BPC-157 from a compounding pharmacy? Not through routine 503A compounding while its current status stands. In 2023 the FDA placed BPC-157 in 503A Category 2, identifying it as a bulk substance that may present significant safety risks and is not eligible for the enforcement discretion that applies to Category 1 substances [20][22]. It is scheduled for advisory-committee discussion in July 2026, which is an evaluation step, not a decision [21]. ## What is the FDA 503A status of BPC-157? The FDA placed BPC-157 ("free base" and "acetate" entries) in 503A Category 2 — bulk drug substances that may present significant safety risks — effective with its September 29, 2023 nominated-substances update [22]. Category 2 substances are not within the FDA's enforcement-discretion policy for 503A compounding, and BPC-157 is not an FDA-approved drug [20]. --- A Material knowledge-panel reading of the BPC-157 record — each finding chipped ESTABLISHED, PRECLINICAL, or CAUTION against its source, the 503A status read first, and no clinic behind the panel and nothing here to dispense.